Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Toxicol Lett ; 225(2): 305-10, 2014 Mar 03.
Artigo em Inglês | MEDLINE | ID: mdl-24374050

RESUMO

Bilitranslocase (BTL) is a plasma membrane carrier that transports organic anions of physiological and pharmacological interest. It is expressed in basolateral plasma membrane of kidney and liver. BTL has been recently described as a marker of transition from normal tissue to its neoplastic transformation in human kidney. Inorganic mercury is a major environmental contaminant that produces many toxic effects. Previous reports have described an interaction between BTL and mercuric ions. This study was designed to evaluate the renal and hepatic expression of BTL in rats exposed to a nephrotoxic and hepatotoxic dose of HgCl2. Male rats were treated with a single injection of HgCl2 at a dose of 4mg/kg body wt, i.p. (HgCl2 group). Control rats received the vehicle alone (Control group). Studies were carried out 18h after injection. Afterwards, the kidneys and livers were excised and processed for histopathological studies or immunoblot (homogenates and crude membranes) techniques. In rats treated with HgCl2, immunoblotting showed a significant decrease in the abundance of BTL in homogenates and plasma membranes from kidney and liver. BTL decrease of expression might reflect the grade of damage in renal tubule cells and in hepatocytes. Thus, BTL might be postulated as a new biomarker of tissue toxicity induced by mercury.


Assuntos
Rim/efeitos dos fármacos , Fígado/efeitos dos fármacos , Proteínas de Membrana/metabolismo , Cloreto de Mercúrio/toxicidade , Animais , Aspartato Aminotransferases/sangue , Biomarcadores/metabolismo , Peso Corporal/efeitos dos fármacos , Ceruloplasmina , Regulação da Expressão Gênica , Rim/enzimologia , Fígado/enzimologia , Masculino , Proteínas de Membrana/genética , Mercúrio/urina , Tamanho do Órgão/efeitos dos fármacos , Ratos , Ratos Wistar
2.
World J Gastroenterol ; 18(44): 6387-97, 2012 Nov 28.
Artigo em Inglês | MEDLINE | ID: mdl-23197884

RESUMO

Obstructive jaundice occurs in patients suffering from cholelithiasis and from neoplasms affecting the pancreas and the common bile duct. The absorption, distribution and elimination of drugs are impaired during this pathology. Prolonged cholestasis may alter both liver and kidney function. Lactam antibiotics, diuretics, non-steroidal anti-inflammatory drugs, several antiviral drugs as well as endogenous compounds are classified as organic anions. The hepatic and renal organic anion transport pathways play a key role in the pharmacokinetics of these compounds. It has been demonstrated that acute extrahepatic cholestasis is associated with increased renal elimination of organic anions. The present work describes the molecular mechanisms involved in the regulation of the expression and function of the renal and hepatic organic anion transporters in extrahepatic cholestasis, such as multidrug resistance-associated protein 2, organic anion transporting polypeptide 1, organic anion transporter 3, bilitranslocase, bromosulfophthalein/bilirubin binding protein, organic anion transporter 1 and sodium dependent bile salt transporter. The modulation in the expression of renal organic anion transporters constitutes a compensatory mechanism to overcome the hepatic dysfunction in the elimination of organic anions.


Assuntos
Ácidos e Sais Biliares/metabolismo , Colestase Extra-Hepática/metabolismo , Icterícia Obstrutiva/metabolismo , Rim/metabolismo , Fígado/metabolismo , Transportadores de Ânions Orgânicos/metabolismo , Adaptação Fisiológica , Animais , Transporte Biológico , Humanos , Preparações Farmacêuticas/metabolismo , Farmacocinética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA